Neoleukin Therapeutics Performance
| NLTXDelisted Stock | USD 0.69 0.01 1.43% |
The company secures a Beta (Market Risk) of -0.11, which conveys not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Neoleukin Therapeutics are expected to decrease at a much lower rate. During the bear market, Neoleukin Therapeutics is likely to outperform the market. Neoleukin Therapeutics right now secures a risk of 0.0%. Please verify Neoleukin Therapeutics total risk alpha, kurtosis, as well as the relationship between the Kurtosis and market facilitation index , to decide if Neoleukin Therapeutics will be following its current price movements.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Neoleukin Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong basic indicators, Neoleukin Therapeutics is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors. ...more
| Begin Period Cash Flow | 143.3 M | |
| Total Cashflows From Investing Activities | -59.1 M |
Neoleukin |
Neoleukin Therapeutics Relative Risk vs. Return Landscape
If you would invest 69.00 in Neoleukin Therapeutics on August 28, 2024 and sell it today you would earn a total of 0.00 from holding Neoleukin Therapeutics or generate 0.0% return on investment over 90 days. Neoleukin Therapeutics is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Neoleukin, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Neoleukin Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Neoleukin Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Neoleukin Therapeutics, and traders can use it to determine the average amount a Neoleukin Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| NLTX |
Based on monthly moving average Neoleukin Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Neoleukin Therapeutics by adding Neoleukin Therapeutics to a well-diversified portfolio.
Neoleukin Therapeutics Fundamentals Growth
Neoleukin Stock prices reflect investors' perceptions of the future prospects and financial health of Neoleukin Therapeutics, and Neoleukin Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Neoleukin Stock performance.
| Return On Equity | -0.38 | |||
| Return On Asset | -0.19 | |||
| Current Valuation | (35.02 M) | |||
| Shares Outstanding | 2.35 M | |||
| Price To Earning | (4.60) X | |||
| Price To Book | 0.44 X | |||
| EBITDA | (56.48 M) | |||
| Cash And Equivalents | 116.46 M | |||
| Cash Per Share | 2.73 X | |||
| Total Debt | 12.07 M | |||
| Debt To Equity | 0.11 % | |||
| Book Value Per Share | 34.18 X | |||
| Cash Flow From Operations | (45.61 M) | |||
| Earnings Per Share | (12.28) X | |||
| Total Asset | 115.95 M | |||
| Retained Earnings | (451.06 M) | |||
| Current Asset | 289 K | |||
| Current Liabilities | 1.02 M | |||
About Neoleukin Therapeutics Performance
Evaluating Neoleukin Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Neoleukin Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Neoleukin Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington. Neoleukin Therapeutics operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 79 people.Things to note about Neoleukin Therapeutics performance evaluation
Checking the ongoing alerts about Neoleukin Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Neoleukin Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Neoleukin Therapeutics is now traded under the symbol NGNE. Please update your portfolios or report it if you believe this is an error. Report It! | |
| Neoleukin Therapeutics is not yet fully synchronised with the market data | |
| Neoleukin Therapeutics has some characteristics of a very speculative penny stock | |
| Neoleukin Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (57.56 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Neoleukin Therapeutics currently holds about 116.46 M in cash with (45.61 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.73, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 16.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Neoleukin Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Neoleukin Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Neoleukin Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Neoleukin Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Neoleukin Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Neoleukin Therapeutics' stock. These opinions can provide insight into Neoleukin Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Other Consideration for investing in Neoleukin Stock
If you are still planning to invest in Neoleukin Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Neoleukin Therapeutics' history and understand the potential risks before investing.
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios |